Pelvis Adaptive Radiotherapy (ART)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRoyal North Shore Hospital

About this trial

Pelvis Adaptive radiotherapy (ART) is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for cancer patients having radiotherapy in the pelvic region.

Adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. Adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced.

Phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. If phase 1 of this study is safe and feasible, the study will proceed to phase 2. Phase 2 of the study looks at using adaptive technology to reduce radiation treatment margins. The primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for patients with cancer in the pelvic area.

Eligibility criteria

Qualifiers

Age > 18

ECOG performance status 0-2

Prostate cancer where nodal treatment is required

Prostate cancer post prostatectomy

Disqualifiers

Hip prosthesis

Patient separation from approximate radiation centre to skin edge > 24cm, measured on diagnostic scan

Trial design

Treatments tested in this trial

  • Adaptive radiotherapy +/- margin reduction
  • Image guided radiotherapy

Treatment groups

280 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Royal North Shore Hospital

Lead sponsor

Northern Sydney and Central Coast Area Health Service

Collaborator